Pear Therapeutics, Inc., the leader in prescription digital therapeutics
(PDTs), today announced that Christopher D.T. Guiffre, J.D., M.B.A.,
Chief Financial Officer and Chief Operating Officer, will participate in
the Oppenheimer Summit for Emerging Biotechnology being held June 27-28
in Montauk, New York.
Pear Therapeutics is a privately held, prescription digital therapeutics
company developing clinically validated, FDA-authorized software
applications to treat serious disease.
About Pear Therapeutics
Pear Therapeutics is the
leader in prescription digital therapeutics. We aim to redefine medicine
by discovering, developing, and delivering clinically validated
software-based therapeutics to provide better outcomes for patients,
smarter engagement and tracking tools for clinicians, and cost-effective
solutions for payers. Pear has a pipeline of products and product
candidates across therapeutic areas, including severe psychiatric and
neurological conditions. Our lead product, reSET®, treats
Substance Use Disorder and was the first prescription digital
therapeutic to receive marketing authorization from the FDA to treat
disease. Pear’s second product, reSET-O®, for the treatment
of Opioid Use Disorder, received marketing authorization from the FDA in
December 2018. For more information, visit us at www.peartherapeutics.com.